AFP and hepatocellular carcinoma: For differentiating very early HCC from non-HCC, thioredoxin had an AUROC of 0.901, sensitivity of 75.2%, and specificity of 88.9%, which were higher than that of AFP (AUROC 0.769, sensitivity 70.1%, specificity 79.4%) (110).